

NOTIFICATION OF PARTICIPATION AND FORM FOR ADVANCE VOTING

by postal voting in accordance with section 22 of the Act (2020:198) on temporary exceptions to facilitate the execution of general meetings in companies and other associations

To be received by IBT no later than May 3, 2021.

The shareholder set out below hereby notifies the company of its participation and exercises its voting right for all of the shareholder's shares in Infant Bacterial Therapeutics AB (publ), org.nr 556873-8586, at the annual general meeting on May 4, 2021. The voting right is exercised in accordance with the voting options marked below.

| Shareholder | Personal identity number/registration number |
|-------------|--|
| | |

Assurance (if the undersigned is a legal representative of a shareholder who is a legal entity): I, the undersigned, am a board member, the CEO or a signatory of the shareholder and solemnly declare that I am authorised to submit this advance vote on behalf of the shareholder and that the contents of the advance vote correspond to the shareholder's decisions

Assurance (if the undersigned represents the shareholder by proxy): I, the undersigned, solemnly declare that the enclosed power of attorney corresponds to the original and that it has not been revoked

| | |
|-----------------------------------|---------------|
| Place and date | |
| | |
| Signature | |
| | |
| Clarification of signature | |
| | |
| Telephone number | E-mail |
| | |

Instructions:

- Complete the information above
- Select the preferred voting options below
- Print, sign and send the form in the original to Infant Bacterial Therapeutics AB (publ), Bryggargatan 10, SE-111 21 Stockholm, Sweden. A completed and signed form may also be submitted electronically and shall, in such case, be sent to ibt@ibtherapeutics.com.

- If the shareholder is a natural person who is personally voting in advance, it is the shareholder who should sign under *Signature* above. If the advance vote is submitted by a proxy of the shareholder, it is the proxy who should sign. If the advance vote is submitted by a legal representative of a legal entity, it is the representative who should sign
- A power of attorney shall be enclosed if the shareholder votes in advance by proxy. If the shareholder is a legal entity, a registration certificate or a corresponding document for the legal entity shall be enclosed with the form
- **Please note that a shareholder whose shares are registered in the name of a bank or securities institute must register its shares in its own name to vote.** Instructions regarding this are included in the notice convening the meeting

A shareholder cannot give any other instructions than selecting one of the options specified at each item in the form. If a shareholder wishes to abstain from voting in relation to a matter, kindly refrain from selecting an option. A vote (*i.e.* the advance vote in its entirety) is invalid if the shareholder has provided the form with specific instructions or conditions or if pre-printed text is amended or supplemented. One form per shareholder will be considered. If more than one form is submitted, the form with the latest date will be considered. The form latest received by the company will be considered if two forms are dated at the same date. An incomplete or wrongfully completed form may be discarded without being considered.

The form, together with any enclosed authorisation documentation, shall be received by IBT no later than May 3, 2021. An advance vote can be withdrawn up to and including May 3, 2021 by contacting IBT at the abovementioned addresses.

For complete proposals regarding the items on the agenda, kindly refer to the notice convening the meeting and complete proposals on IBT's website. The complete proposals are provided on the company's website no later than three weeks before the annual general meeting.

For information on how your personal data is processed, see the integrity policy that is available at Euroclear's website www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf.

Annual general meeting in Infant Bacterial Therapeutics on May 4, 2021

The voting options below comprise, if not otherwise stated in the form, the proposals included in the notice convening the annual general meeting.

| |
|---|
| <p>1. Election of a chairman of the meeting</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p> |
| <p>2. Selection of one or two persons to attest the minutes of the meeting</p> |
| <p>2.1 Jannis Kitsakis or, to the extent he is prevented, the person assigned by the nomination committee</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p> |
| <p>2.2 Sten Irwe or, to the extent he is prevented, the person assigned by the nomination committee</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p> |
| <p>3. Establishment and approval of the voting list</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p> |
| <p>4. Approval of agenda</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p> |
| <p>5. Resolution as to whether the meeting has been duly convened</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p> |
| <p>6</p> |
| <p>7a. Decision to determine the income statement and balance sheet and the consolidated income statement and consolidated balance sheet</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p> |
| <p>7b. Decision on disposals of the company's income according to the established balance sheet</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p> |
| <p>7c. Decision on discharge from liability for the board members and the managing director</p> |
| <p>1. Peter Rothschild</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p> |
| <p>2. Anders Ekblom</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p> |
| <p>3. Margareta Hagman</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p> |
| <p>4. Lilian Henningson Wikström</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p> |

| |
|---|
| 5. Eva Idén Yes <input type="checkbox"/> No <input type="checkbox"/> |
| 6. Anthon Jahreskog Yes <input type="checkbox"/> No <input type="checkbox"/> |
| 7. Kristina Sjöblom Nygren Yes <input type="checkbox"/> No <input type="checkbox"/> |
| 8. Staffan Strömberg Yes <input type="checkbox"/> No <input type="checkbox"/> |
| 8. Resolution regarding the number of board members and auditors |
| 8.1 Number of board members Yes <input type="checkbox"/> No <input type="checkbox"/> |
| 8.2 Number of auditors Yes <input type="checkbox"/> No <input type="checkbox"/> |
| 9. Determinations of fees to the board of directors and auditor |
| 9.1 Fees to the board Yes <input type="checkbox"/> No <input type="checkbox"/> |
| 9.2 Fees to the auditors Yes <input type="checkbox"/> No <input type="checkbox"/> |
| 10. Election of board members |
| 1. Margareta Hagman Yes <input type="checkbox"/> No <input type="checkbox"/> |
| 2. Eva Idén Yes <input type="checkbox"/> No <input type="checkbox"/> |
| 3. Anthon Jahreskog Yes <input type="checkbox"/> No <input type="checkbox"/> |
| 4. Kristina Sjöblom Nygren Yes <input type="checkbox"/> No <input type="checkbox"/> |
| 5. Peter Rothschild Yes <input type="checkbox"/> No <input type="checkbox"/> |
| 6. Robert Molander Yes <input type="checkbox"/> No <input type="checkbox"/> |
| 11. Election of the chairman of the board |
| 1. Peter Rothschild |

Yes No

12. Election of auditor

1. Deloitte AB

Yes No

13. Resolution regarding the nominating committee

Yes No

14. Resolution regarding principles for remuneration to senior executives

Yes No

15. Resolution regarding the Board's proposal for a resolution regarding mandate for a new issuance of shares

Yes No

The shareholder wishes that the resolutions under one or several items in the form above be deferred to a continued general meeting
(Completed only if the shareholder has such a wish)

Item/items, use numbering: